Literatura académica sobre el tema "Dina galli"

In mediaeval Gallo-Romance, due to regular sound change, the reflexes of Latin perfectum forms develop stem allomorphy linked to alternation between rhizotonic and arrhizotonic stress. Both the allomorphy and the stress alternation are subsequently eradicated. By contrast, in early Italo-Romance, existing stem allomorphy is redistributed by analogy so that, in the reflexes of Latin perfectum forms, stem alternation and stress alternation have the same distribution, a situation which persists into modern Italo-Romance. These developments illustrate a tendency for the exponents of morphomic distributions to be aligned with one another, facilitating reliable inferences about the forms realising different paradigm cells.

Abstract All modern Basque dialects have at least 5 contrastive vowels /i, e, a, o, u/. One Basque dialect, Zuberoan, has developed a contrastive sixth vowel, the front rounded high vowel /y/. This development is arguably due to sustained contact with neighboring Gallo-Romance languages. This paper supports empirically the historical development of the /u/ vs. /y/ contrast and provides a detailed analysis of the contexts that inhibited the /u/ > /y/ sound change. Fronting was inhibited when the vowel was followed by an apical sibilant, a tap /ɾ/ or an rT cluster (where r is a rhotic, and T an alveolar obstruent), arguably due to coarticulatory effects. Fronting occurred when /s̻/, /r/ or non-coronal rhotic-obstruent clusters followed /u/. Zuberoan /u/-fronting illustrates the importance of language contact and phonetics in the phonological analysis of historical developments.

Abstract Background Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report baseline characteristics associated with clinical improvement at day (d) 14. Methods We enrolled hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation >94% on room air, and radiological evidence of pneumonia. Patients were randomized 1:1:1 to receive 5d or 10d of intravenous RDV once daily plus standard of care (SoC), or SoC only. For this analysis, patients were followed through discharge, d14, or death. Baseline demographic and disease characteristics associated with clinical improvement in oxygen support (≥2-point improvement on a 7-category ordinal scale ranging from discharge to death) were evaluated using multivariable logistic regression methods. Results 584 patients were randomized and treated (5/10d RDV, n=384; SoC: n=200). 159 (27%) were ≥65y, 227 (39%) female, 328 (61%) white, 102 (19%) Asian, and 99 (19%) Black. 252 participants (43%) were enrolled in Europe, 260 (45%) North America (NA), and 72 (12%) in Asia. Most patients (483 [83%]) were not on supplemental oxygen but required medical care at baseline. In a multivariable model, 5/10d RDV was significantly positively associated with clinical improvement (adjusted odds ratio [OR] 1.69, 95% CI: 1.08, 2.65; p=0.0226). Significant covariables positively associated with clinical improvement included age < 65y (p< 0.0001) and region of treatment (Europe and NA vs Asia, p< 0.0001 each; Table); other examined factors were not significantly associated with clinical improvement, including gender, race, ethnicity, baseline oxygen support, duration of symptoms and hospitalization, obesity, and baseline transaminase levels. Table 1. Conclusion In moderate COVID-19 patients, after adjusting for treatment arm, age < 65y and region (NA vs Asia; Europe vs Asia) were associated with higher rates of clinical improvement. These observations recapitulate younger age as positive prognostic factor, and highlight the differences in the impact of the pandemic globally. Disclosures Antonella Castagna, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Shu Cheong Hui, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Kathleen M. Mullane, DO, PharmD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator) Mamta Jain, MD, Gilead Sciences Inc. (Scientific Research Study Investigator, Research Grant or Support)GlaxoSmithKline (Advisor or Review Panel member)Janssen (Research Grant or Support)Merck (Research Grant or Support) Massimo Galli, MD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Personal fees) Shan-Chwen Chang, MD, PhD, Gilead Sciences Inc. (Scientific Research Study Investigator) Robert H. Hyland, MD, Gilead Sciences Inc. (Employee, Shareholder) Devi SenGupta, MD, Gilead Sciences Inc. (Employee, Shareholder) Huyen Cao, MD, Gilead Sciences Inc. (Employee, Shareholder) Hailin Huang, PhD, Gilead Sciences Inc. (Employee, Shareholder) Anand Chokkalingam, PhD, Gilead Sciences (Employee) Anu Osinusi, MD, Gilead Sciences (Employee) Diana M. Brainard, MD, Gilead Sciences (Employee) Christoph Lübbert, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Chien Boon Lye, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Chien Boon Lye, MD, NO DISCLOSURE DATA Judith A. Aberg, MD, Theratechnology (Consultant) Enrique Navas Elorza, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Karen T. Tashima, MD, Bristol-Myers Squibb (Research Grant or Support)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator)GlaxoSmithKline (Research Grant or Support)Merck (Research Grant or Support)Tibotec (Research Grant or Support)Viiv Healthcare (Research Grant or Support) Mark McPhail, MD, Gilead Sciences Inc. (Scientific Research Study Investigator)

Abstract Background Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. Methods We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence of pulmonary infiltrates, and oxygen saturation >94% on room air. Patients were randomly assigned 1:1:1 to receive up to 5d or 10d of RDV with standard of care (SoC), or SoC alone; patients could be discharged prior to completing per-protocol assigned treatment duration. RDV was dosed intravenously at 200 mg on d1, 100 mg daily thereafter. Patients were evaluated daily while hospitalized, and via telephone if discharged. The primary endpoint was clinical status on d11 assessed on a 7-point ordinal scale. Results regarding the primary endpoint are expected to be published before IDWeek 2020; we plan to present d28 results at the meeting. Results In total, 584 patients underwent randomization and started their assigned treatment (191, 5d RDV; 193, 10d RDV; 200, SoC). By d11, ³ 2 point improvement on the ordinal scale occurred in 70% of patients in the 5d arm, 65% in the 10d arm, and 61% in the SoC arm. Patients in the 5d RDV arm were significantly more likely to have an improvement in clinical status than those receiving SoC (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.09–2.48; P=0.017); OR of improvement for the 10d RDV arm compared to SoC was 1.31 (95% CI, 0.88–1.95]; p=0.183). This improvement in the 5-day arm over the SOC arm was noted from d6 through d11. We observed a peak of discharges corresponding with the assigned treatment duration of RDV, with increased discharges at d6 in the 5-day arm and at d11 in the 10-day arm. A worsening of clinical status of ≥ 1 point in the ordinal scale was observed more commonly in the SoC am (n=19, 10%) versus the 5d RDV (n=7, 4%) and 10d RDV (n=9, 5%). Conclusion RDV for up to 5 days was superior to SoC in improving the clinical status of patients with moderate COVID-19 by d11. We will report d28 outcomes at the meeting. Disclosures Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Prashant Malhotra, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Robert L. Gottlieb, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Karen T. Tashima, MD, Bristol-Myers Squibb (Research Grant or Support)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator)GlaxoSmithKline (Research Grant or Support)Merck (Research Grant or Support)Tibotec (Research Grant or Support)Viiv Healthcare (Research Grant or Support) Massimo Galli, MD, Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Personal fees) Louis Yi Ann Chai, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Devi SenGupta, MD, Gilead Sciences Inc. (Employee, Shareholder) Robert H. Hyland, MD, Gilead Sciences Inc. (Employee, Shareholder) Hongyuan Wang, PhD, Gilead Sciences Inc. (Employee, Shareholder) Lijie Zhong, PhD, Gilead Sciences Inc. (Employee, Shareholder) Huyen Cao, MD, Gilead Sciences Inc. (Employee, Shareholder) Anand Chokkalingam, PhD, Gilead Sciences (Employee) Anu Osinusi, MD, Gilead Sciences (Employee) Diana M. Brainard, MD, Gilead Sciences (Employee) Michael Brown, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Ane Josune Goikoetxea, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Mamta Jain, MD, Gilead Sciences Inc. (Scientific Research Study Investigator, Research Grant or Support)GlaxoSmithKline (Advisor or Review Panel member)Janssen (Research Grant or Support)Merck (Research Grant or Support) David Shu Cheong Hui, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Enos Bernasconi, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Christoph Spinner, MD, AbbVie (Advisor or Review Panel member, Other Financial or Material Support, Travel)Bristol-Myers Squibb (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Gilead Sciences Inc. (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member, Other Financial or Material Support, Travel)Janssen (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)MSD (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)Viiv Healthcare (Grant/Research Support, Advisor or Review Panel member, Other Financial or Material Support, Travel)

Trained in the great family of Edoardo Ferravilla’s Milanese dialect companies, in early twentieth century Dina Galli becomes one of the greatest comic actresses of Italian scene. She plays with great contemporary actors such as Virgilio Talli and Antonio Gandusio and she explores all the expressive languages of performance: theater, radio and cinema.

Trained at the acting school of Luigi Rasi in Florence, Amerigo Guasti affirmed himself as appreciated Brillante between 19th and 20th century. As well as being a good interpreter, he is a skilled ‘Capocomico’ and director of his own companies. Since 1906 he establishes a permanent collaboration with Dina Galli. He is also a translator and author of dramatic texts, newspaper articles and an autobiographical book.

Introduction: Irvingia gabonensis belongs to the Irvingiaceae plant family and commonly known as the African bush mango, wild mango, Dika nut and Manguier sauvage. The fruits of I. gabonensis are edible and their use in traditional medicine has been reported for the treatment of diabetes, diarrhea, wound ulcer, hepatic disorder, microbial infections, and inflammatory pains. Aim: This study aimed to identify the standard phenolic contents of I. gabonensis fruit pulp and peel extracts and investigate the bind energy on polyphenol oxidase in order to know why browning of I. gabonensis fruit is often rapidly occur and how to prevent it with suitable inhibitor in an industrial processing. Results: The phenolics that were identified include ellagic acid, cinnamic acid, gallic acid, 3-friedelanone, lupeol, kaempferol, quercetin, alpha-curcumene and zingiberene. The two PPO from Solanum lycopersicum (PDB ID: 6HQI) and Mangifera indica (PDB: D2XZ13_model) have different binding energies across the ligands with highest score by 3-friedelanone (-14.3 and -16.1 kcal/mol respectively), followed by lupeol (-13.9 and -14.6 kcal/mol respectively). The differences in the binding energies across the plant PPOs could be due to variation in the amino acid composition and more importantly the amino acid residues that participate in the catalytic and allosteric activities Conclusion: This study has shown the reason behind rapid browning that usually occur in I. gabonensis and more importantly, the need for effective edible inhibitors of PPO.

ABSTRAK Penelitian ini bertujuan untuk menentukan aktivitas antifotoksidasi mengukur nilai SPF dari ekstrak metanol daun Gedi (Abelmoschus manihot L). Daun gedi diekstraksi dengan cara sokletasi. Dalam penelitian ini sampel diekstraksi dengan pelarut metanol, difraksinasi dengan pelarut petroleum eter, etil asetat, butanol dan akuades. Dari hasil fraksinasi tersebut kemudian diuji aktivitas antifotooksidasi dan fotoprotektif. Kandungan fenolik menggunakan asam galat sebagai larutan standart. Uji Aktivitas antifotooksidasi ditentukan dengan menghitung nilai diena terkojugasi yang merupakan pembentukan awal oksidasi pada lipid. Semakin rendah nila diena terkonjugasi, maka semakin baik sebagai antifotooksidasi. Untuk penentuan fotoprotektif, dilakukan dengan mneggunakan spektrofotometer UV-Vis pada panjang gelombang 290-320 nm dengan konsentrasi 100 μg/mL. Hasil penelitian ini menunjukkan bahwa fraksi etil asetat memiliki kandungan fenolik, aktivitas antioksidan, antifotooksidasi, dan fotoprotektif yang paling tinggi. Hasil yang diperoleh menunjukkan total fenol paling tinggi pada fraksi eti asetat yaitu 110.204 µg/mL, sedangkan untuk aktivitas antioksidan 57.72%. Hasil pada aktivitas antifotooksidasi menunjukkan bahwa fraksi Etil asetat menunjukkan kemampuan yang paling baik dan untuk fotoprotektik memiliki nilai SPF yang tinggi adalah etil asetat yaitu 9.03. ABSTRACT This study aimed to determine the antifotoxidation activity measuring the SPF value of the solvent fraction of the leaves of Gedi (Abelmoschus manihot L). Gedi leaves extracted by socletation. In this study the samples were extracted with methanol solvent, fractionated with petroleum ether, ethyl acetate, butanol and aquades. The results of the fractionation were then tested for antifotooxidation and photoprotective activity. Phenolic content uses gallic acid as a standard solution. The antifotoxidation activity test is determined by calculating the conjugated diene value which is the initial formation of oxidation in the lipid. The lower the conjugated diene tilapia, the better it is antifotoxidation. For photoprotective determination, a UV-Vis spectrophotometer was carried out at a wavelength of 290-320 nm with a concentration of 100 μg / mL. The results of this study indicate that the highest ethyl acetate fraction has the highest phenolic content, antioxidant activity, antifotoxidation and photoprotective. The results obtained showed the highest total phenol in the eti acetate fraction of 110,204 µg / mL, while for antioxidant activity 57.72%. The results of the anti photoxidation activity showed that the ethyl acetate fraction showed the best ability and for the photoprotectic the high SPF value was ethyl acetate namely 9.03.

Il progetto di ricerca si inserisce in un preciso solco di studi relativo al funzionamento del sistema e l’evoluzione dei ruoli del teatro italiano nel corso del XIX secolo. In particolare l’indagine è rivolta a quei ruoli che, detentori della comicità al femminile, compiono un processo che conduce dalla servetta di primo Ottocento fino alla prima attrice comica di fine secolo. La trattazione racconta la morte di un ruolo, quello della servetta legata alla drammaturgia goldoniana, e la sopravvivenza delle sue peculiarità in altri ruoli (espresse anche a livello drammaturgico) grazie all'estro delle singole interpreti; racconta della trasformazione dei tratti della comicità femminile a livello di ruoli teatrali fino alla sua consacrazione in quel ruolo codificato di prima attrice comica di fine secolo, incarnato alla perfezione da Dina Galli.

This contribution provides evidence for a predicate focus analysis of Gascon que, based on unpublished dialectological material gathered in the 1970s in the Occitan area. Even though Pusch (2000: 201) observes that ‘any dia- or panchronic account of Gascon enunciatives inevitably remains conjectural, since we lack sufficient textual data from earlier stages of this Occitan variety’, the data of the locality of Les Esseintes discussed in this paper clearly show that the particle que is used in the context of a fossilized cleft sentence.

This material results from the research of the nut culture in order to identify pathogenic organisms of the class Arachnida and to represent the effects of these organisms on tree organs. The research was made at the Botanical Garden Institute, Chișinău on a number of 300 trees. This paper includes the identification of the main pests of the class Arachnida, namely: the gall mite of walnut leaves (Aceria tristriata) and the disease named walnut blister mine caused by Aceria erinea. At the same time, the methods of pest control and the negative effects of their presence are exposed here.